Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 May;45(5):e70018.
doi: 10.1111/liv.70018.

Therapeutic Plasma Exchange in Patients With Acute-On-Chronic Liver Failure Improves Survival-An Updated Meta-Analysis

Santhosh E Kumar  1 , Kausala Sithamparapillai  2 , Ashok Kumar Choudhury  3 , P Krishna Bharadwaj  1 , Jonel Trebicka  4 , Constantine J Karvellas  5 , Juan Pablo Arab  6 , Prasanna Samuel Premkumar  7 , C E Eapen  1 , Ashish Goel  1
Affiliations
Meta-Analysis

Therapeutic Plasma Exchange in Patients With Acute-On-Chronic Liver Failure Improves Survival-An Updated Meta-Analysis

Santhosh E Kumar et al. Liver Int. 2025 May.

Abstract

Background and aim: Acute-on-chronic liver failure (ACLF) is a syndrome that develops after an acute insult and is associated with organ failures and high short-term mortality. Plasma exchange (PLEX) is an emerging modality for treating ACLF patients. We aimed to evaluate the efficacy of PLEX in treating ACLF.

Methods: We conducted a systematic review and meta-analysis of studies comparing PLEX versus standard medical therapy (SMT) to treat patients with ACLF across different definitions and etiologies. Pooled risk ratios were determined by the Mantel-Haenszel method within a random effect model. The primary outcome studied was survival at 30 days in PLEX group compared to SMT.

Results: Twenty-three studies (5336 ACLF patients with 2724 in PLEX arm, including 4 RCTs) were included. PLEX was associated with a significant reduction in mortality at 30 days (RR 0.70; 95% CI, 0.60-0.81; p < 0.001) and at 90 days (RR 0.81;0.77-0.86; p < 0.001). Six studies (1495 patients; 2 RCTs) with data for 1-year survival showed better outcomes in the PLEX group (RR 0.85; 0.79-0.92; p < 0.0001) compared to SMT. Among HBV-related ACLF and alcohol-related ACLF, there was a significant reduction in mortality among PLEX treated group at 90 days; RR 0.79 (0.74-0.85), p < 0.001 and RR 0.69 (0.52-0.92), p = 0.01 respectively. PLEX was associated with improved 3-month survival across definitions for ACLF. The most common adverse effects were skin rash and allergic reactions (14%).

Conclusions: In this up-to-date meta-analysis, significant 1, 3-month and up to 1-year survival benefit was noted among patients with ACLF treated with PLEX compared to SMT.

Keywords: alcohol; artificial liver support system; hepatitis B virus; liver transplant.

PubMed Disclaimer

References

    1. H. Ohnishi, J. Sugihara, H. Moriwaki, and Y. Muto, “Acute‐On‐Chronic Liver Failure,” Ryōikibetsu Shōkōgun Shirīzu 7 (1995): 217–219.
    1. T. Wu, J. Li, L. Shao, et al., “Development of Diagnostic Criteria and a Prognostic Score for Hepatitis B Virus‐Related Acute‐On‐Chronic Liver Failure,” Gut 67, no. 12 (2018): 2181–2191.
    1. R. Moreau, R. Jalan, P. Gines, et al., “Acute‐On‐Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis,” Gastroenterology 144, no. 7 (2013): 1426–1437.e9.
    1. J. G. O'Leary, K. R. Reddy, G. Garcia‐Tsao, et al., “NACSELD Acute‐On‐Chronic Liver Failure (NACSELD‐ACLF) Score Predicts 30‐Day Survival in Hospitalized Patients With Cirrhosis,” Hepatology 67, no. 6 (2018): 2367–2374.
    1. S. K. Sarin, C. K. Kedarisetty, Z. Abbas, et al., “Acute‐On‐Chronic Liver Failure: Consensus Recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014,” Hepatology International 8, no. 4 (2014): 453–471.

MeSH terms

LinkOut - more resources